Cognitive dysfunction is a common symptom of Parkinson ' s disease (PD) that causes significant morbidity and mortality. The severity of these symptoms ranges from minor executive symptoms to frank dementia involving multiple domains. In the present review, we will concentrate on the aspects of cognitive impairment associated with prefrontal dopaminergic dysfunction, seen in non-demented patients with PD. These symptoms include executive dysfunction and disorders of thought, such as hallucinations and psychosis. Such symptoms may go on to predict dementia related to PD, which involves amnestic dysfunction and is typically seen later in the disease. Cognitive symptoms are associated with dysfunction in cholinergic circuits, in addition to the abnormalities in the prefrontal dopaminergic system. These circuits can be carefully studied and evaluated in PD, and could be leveraged to treat difficult clinical problems related to cognitive symptoms of PD.
Introduction
Parkinson ' s disease (PD) is a neurodegenerative condition in which midbrain dopamine neurons inexorably die (Hughes et al., 1992) resulting in impaired motor function (Fahn et al., 2004) . Recently, non-motor symptoms have been recognized as a prominent part of PD (Chaudhuri and Schapira, 2009 ). These symptoms can precede diagnosis of motor symptoms by several decades (Claassen et al., 2010) . One non-motor symptom that causes particular morbidity and mortality in PD is cognitive dysfunction (Santangelo et al., 2007; Forsaa et al., 2010a) . In the present review, we discuss cognitive dysfunction in PD and relate it to processes that localize to the prefrontal cortex. We show how mesocortical dopaminergic projections to the prefrontal cortex can be involved in the genesis of these symptoms, and how these projections interact with ascending cholinergic projections.
Identifying the mechanism of cognitive dysfunction in PD is crucial for treating cognitive symptoms of PD, as currently we have few effective treatments for this difficult clinical problem. Levodopa inconsistently improves cognitive symptoms of PD (M ü ller et al., 2001; Cools, 2006; Pascual-Sedano et al., 2008) , depending on disease state and the integrity of striatal dopamine signaling (Cools et al., 2001) . Some data suggest that cholinesterase inhibitors can be somewhat beneficial for executive symptoms of PD (Reading et al., 2001; Poewe et al., 2006; Schmitt et al., 2010) in addition to their known benefits for dementia (Emre et al., 2004) . Further elucidation of how these circuits influence cognition in PD may help rationally target therapies for this difficult clinical problem.
Spectrum of cognitive dysfunction in PD
Although mild visuospatial and amnestic impairments can also be seen, typically non-demented PD patients can manifest executive dysfunction with no amnestic component at incident diagnosis of PD (Foltynie et al., 2004a; Aarsland et al., 2009 ). These include impaired working memory, planning, attention , decreased speed of processing (Uc et al., 2005) , impulse control disorders (ICDs) (Pontone et al., 2006) associated with dopamine agonists (Weintraub et al., 2006) , and disordered thought (Factor et al., 2003) . These are distinct from fluctuating disturbances of memory, calculation, visuospatial function, and behavioral control associated diffusely with Lewy body dementia (Lennox, 1992; McKeith et al., 1996) and PD-related dementia (Aarsland et al., 2003 (Aarsland et al., , 2009 . Crucially, PD is heterogeneous with respect to cognitive impairments, complicating interpretation of clinical data thus far (Wurtman, 2012) . In addition, epidemiological studies draw on a diversity of methods, and there is no uniform definition of mild cognitive impairment (MCI) in PD .
Cognitive dysfunction is common in PD (Muslimovic et al., 2005) . In early PD, up to 36% of Parkinson ' s patients had some evidence of cognitive impairment at disease onset (Foltynie et al., 2004a) . In a population-based study in Norway of untreated PD (Aarsland et al., 2009 ), 19% of patients had MCI, as defined by poor performance on neuropsychological testing. Interestingly, two-thirds of patients in this category had intact performance on tests that measured amnestic performance. The CamPaIGN study followed 126 PD patients for 5 years from incident diagnosis, and revealed a population with dementia that was unrelated to executive dysfunction, as measured by the Tower of London task (Williams-Gray et al., 2009 ). In a Swedish study, 88 patients with newly diagnosed PD performed consistently worse in neuropsychological testing, and 30% of patients had executive deficits (Elgh et al., 2009 ). This deficit may be independent of overall motor disability (Cooper et al., 1991; Kieburtz et al., 1994) ; however, some studies suggest some patterns linking movement speed and axial signs to cognitive dysfunction (Aarsland et al., 2003; Uc et al., 2009; Domell ö f et al., 2011) .
Cognitive symptoms can be influenced by disease progression. This pattern of both non-amnestic and amnestic patterns of cognitive dysfunction has commonly been observed in multicenter population studies of PD (Aarsland et al., 2009; Dalrymple-Alford et al., 2011; Monastero et al., 2012) . A meta-analysis revealed that, on average, across a diversity of methodologies, 27% of patients with PD had non-amnestic cognitive dysfunction . Several epidemiological studies have revealed that patients with PD develop dementia at four to six times the rate of normal aging (Aarsland et al., 2001 (Aarsland et al., , 2005 Hobson and Meara, 2004) . In a longitudinal study of idiopathic PD, cognitive symptoms continued to develop over the course of the disease at rates much higher than normal aging (Williams-Gray et al., 2007) and are associated with a shorter time to dementia (Aarsland and Kurz, 2010) . Within 5 years of diagnosis, up to 17% of patients developed dementia (Aarsland and Kurz, 2010) . In advanced PD, cognitive symptoms can dominate later stages of the disease (Ferreri et al., 2006) .
At all stages, cognitive dysfunction can cause significant morbidity and mortality (Forsaa et al., 2010a) . These symptoms, at first diagnosis, lead to nearly double the mortality rate in PD (Levy et al., 2002) and predict nursing home placement (Aarsland et al., 2000) . This is associated with significant costs at all stages of the disease (Kaltenboeck et al., 2012) . Even in earlier stages of the disease, cognitive dysfunction can interfere with key activities, such as driving (Stolwyk et al., 2005; Uc et al., 2006 Uc et al., , 2007 Uc et al., , 2011 Crizzle et al., 2012) and predict loss of independence (Uc et al., 2011) . Future observational data on the natural history of cognitive symptoms and dementia in PD will help further define this issue (Balzer-Geldsetzer et al., 2011) .
Executive dysfunction
Executive functions are a group of psychological processes that regulate and control other cognitive processing. These include functions such as working memory, planning, reasoning, timing, and inhibitory control (Baddeley, 1998) . Executive processes can be measured through standard neuropsychological testing, such as clock-drawing, Wisconsin-Card-Sorting, Stroop interference tasks, or trail making (Litvan et al., 1991) , and are distinct from non-executive functions, such as memory, language and motor control. Screening instruments that assay executive function may be useful in PD patients (Dalrymple-Alford et al., 2010 , 2011 .
Patients with very early PD can have impaired executive functions (Caballol et al., 2007 ). An early study reported that executive dysfunction in PD was not correlated with motor function (Van Spaendonck et al., 1996) . As mentioned above, the Norwegian ParkWest study noted MCI among 196 non-demented patients with PD (Aarsland et al., 2009 ), compared to age-matched controls. A multicenter study from the same group of 1346 actively managed patients with PD, found that 26% of PD patients had MCI and 10% had executive dysfunction (Aarsland and Kurz, 2010) . Small studies have reported that dopaminergic therapy does not reliably improve executive dysfunction in high-functioning (Pascual-Sedano et al., 2008) or moderate PD (Morrison et al., 2004) , and can potentially have detrimental effects (Cools et al., 2001; Cools and D ' Esposito, 2011) .
Impulse-control disorders may be viewed as another side of dysexecutive syndrome in PD (Ceravolo et al., 2012) . They can manifest as pathological gambling, hypersexuality, compulsive shopping, and compulsive eating. These were recently detected in up to 13% of structured surveys of Parkinson ' s patients (Voon et al., 2006a) , and prospectively related to exposure to dopamine agonists (Voon et al., 2006b ) that may be dose-dependent . In a large cross-sectional multicenter study, ICDs were found in 13.6% of patients with PD (Weintraub et al., 2010) . In this study, dopaminergic agonists were associated with a 2.5 times greater risk of developing ICDs. Patients who were more likely to develop ICDs were younger, depressed, anxious, impulsive, and obsessive (Weintraub et al., 2010; Voon et al., 2011) . The primary treatment for this disorder is withdrawal of dopaminergic agonists ( Á vila et al., 2011) if practical.
Thought disorders in PD
Disorders of thought are commonly seen in psychiatric diseases, such as schizophrenia or bipolar disorder, and are hypothesized to involve dopaminergic circuitry (Braver et al., 1999) . In PD, which also involves dysfunction in dopamine systems, disorders of thought have been recognized for decades (Knopp, 1970) . A community survey of 245 patients in Norway reported that 10% of patients had symptoms of disordered thought, the risk of which correlated with age and disease severity (Aarsland et al., 1999) . Following this cohort over time suggested that a majority of Parkinson ' s patients experienced thought disorders at some time (Forsaa et al., 2010b ) associated with high doses of levodopa and REM sleep disorder. Such symptoms could be a surrogate of disease severity, and could be associated with poor outcomes, such as nursing home placement, death, and dementia (Factor et al., 2003) . Atypical antipsychotics, such as clozapine (Wolk and Douglas, 1992) , can be effective at controlling hallucinations (Parkinson ' s Study Group, 1999) , and cholinesterase inhibitors have modest benefit (Williams-Gray et al., 2006) . More recently, serotonin 5-HT2A agonists have demonstrated antipsychotic efficacy in both animal models and human subjects (Acadia Pharmaceuticals Press Release, 2012).
Dementia
One hallmark of dementia is that it involves amnestic dysfunction. Some PD patients with cognitive symptoms have no memory loss (Williams-Gray et al., 2006; Aarsland et al., 2009 Aarsland et al., , 2010 . Although executive dysfunction and thought disorders can be seen in other types of dementias (Swanberg et al., 2004; Aarsland and Kurz, 2010) , in PD, these features often predict the early development of dementia (Aarsland and Kurz, 2010; Forsaa et al., 2010b) with associated increases in morbidity and mortality (Forsaa et al., 2010a) . Dementia can be highly prevalent across the entire course of PD, affecting up to 80% of patients (Aarsland et al., 2001 (Aarsland et al., , 2003 Aarsland and Kurz, 2010) , and may be associated with early hallucinations and akinetic-dominant variants of PD (Aarsland et al., 2003; Emre et al., 2007) .
Idiopathic PD involves extensive accumulation of Lewy-bodies, eosinophilic intracellular inclusions within the midbrain. However, they can be observed in normal aging and other dementias (Gibb and Lees, 1988) . One possibility is that Lewy-body pathology spreads from peripheral nuclei to the neocortex (Braak et al., 2003) . This idea has been recently bolstered by the description of cell-to-cell transmission of pathological α-synuclein (Dunning et al., 2012; Luk et al., 2012a,b) . According to this hypothesis, cognitive symptoms of PD would be caused by spread of Lewy-bodies to the cognitive areas of the neocortex, such as medial prefrontal cortex (Huang et al., 2007) .
Indeed, quantitative counts of synuclein pathology seemed to loosely associate with Mini-Mental State Exam, although in this data, there were high-pathological stage PD patients with low impairments, and low pathological stage PD patients with high impairments (Braak et al., 2006) . Multivariate regression of the brains of 148 patients with PD revealed that Braak ' s specific pathological staging was not predictive of dementia (Gibb and Lees, 1988; Burton et al., 2004; Compta et al., 2011; Irwin et al., 2012) . However, distribution of Lewy-body burden did roughly correlate with clinical diagnosis of dementia (Irwin et al., 2012) . These data, while not supporting the explicit rostro-caudal progression of synuclein (Jellinger, 2009) , largely support the Braak hypothesis. However, the specific patterns in PD, PD-related dementia, and Lewybody dementia, are yet to be defined (Lippa et al., 2007) .
Other pathological processes may contribute to cognitive symptoms in PD (Kempster et al., 2010) . For instance, tau and amyloid are common in PD-dementia (Kempster et al., 2010; Compta et al., 2011; Irwin et al., 2012; Kotzbauer et al., 2012) and while these are correlated with PDdementia (Compta et al., 2011) , they shed little insight on cognitive dysfunction present earlier in the disease. Furthermore, the association with Alzheimer ' s risk factors, AB42 (Montine et al., 2010) , ApoE4 (Irwin et al., 2012) , the tau-related gene MAPT (Aarsland and Kurz, 2010) or white matter changes (Kim et al., 2012) suggest that other processes may contribute to cognitive dysfunction in PD.
One possibility is that Alzheimer's disease (AD)-pathology, involving tau and amyloid deposition, contributes to dementia, and separate synuclein-related processes involving cholinergic and dopaminergic systems contribute to executive dysfunction in PD ( Figure 1 ). Future work may be able to perform molecular imaging of synuclein with molecular imaging of AD pathology (Burack et al., 2010) and explicitly test this idea and further define the role of synuclein pathology and cognitive symptoms of PD.
Prefrontal dopamine signaling and executive dysfunction in PD
Executive dysfunction and thought disorders localize to the prefrontal cortex (Baddeley, 1998; Goldman-Rakic, 1998; Fuster, 2008) . For instance, brain imaging of executive processes, such as working memory (Narayanan et al., 2005) , planning (Miller and Cohen, 2001) , conflict monitoring (Botvinick et al., 2004) , inhibitory control (Dias et al., 2006) , and timing (Coull et al., 2011) , reliably show activation of prefrontal regions, including dorsolateral prefrontal cortex (BA 9/46) and medial prefrontal regions (BA 25/32). Diseases that involve impaired executive function, such as schizophrenia, involve deactivation in these regions (Weinberger et al., 1986) . Prefrontal dysfunction has long been linked to disordered thought (Dolan et al., 1993) , and localization of processes that are affected by PD might facilitate insight into possible mechanisms, as any pathophysiological explanation for the cognitive symptoms of PD must account for prefrontal dysfunction.
Neuropsychological evidence reveals that Parkinson ' s patients are impaired on tests that are sensitive to prefrontal function (Zgaljardic et al., 2006) , such as the WisconsinCard-Sorting Task (Gotham et al., 1988) , attentional setshifting (Cools et al., 2001) , and spatial working memory (Lange et al., 1992) . Metabolic imaging evidence has implicated a medial frontal network in which deactivation is correlated with poor performance on cognitive tests (Huang et al., 2007) . Brain imaging studies have consistently demonstrated hypoactivation of prefrontal areas in Parkinson ' s patients. For instance, during a random number generation task, controls activated medial frontal networks more robustly than Parkinson ' s patients (Dirnberger et al., 2005) . The same group observed similar patterns of deactivation during a motor timing task; furthermore, in this task medial frontal activation could be modulated by levodopa (Jahanshahi et al., 2010) . A similar pattern was found in a time perception task (Harrington et al., 2011) . During performance of the Tower of London planning tasks, levodopa restored prefrontal blood flow, as measured by positron emission tomography (PET) (Cools et al., 2002) . Finally, in PD, decreased performance on attentional set-shifting is correlated with impaired metabolic activity in the prefrontal cortex (Sawada et al., 2012) . This line of work consistently describes less prefrontal activity in PD that is correlated with impaired executive performance.
Prefrontal dopamine
Patients with PD have impaired prefrontal dopamine signaling Pillon, 1995, 1997) . Prefrontal regions receive dopamine, not from the nigrostriatal projections, rather, they receive dopamine from the ventral tegmental and medial nigral regions of the midbrain (Williams and Goldman-Rakic, 1998) . These nuclei do degenerate in some patients with PD (Javoy-Agid and Agid, 1980; Javoy-Agid et al., 1981; Dymecki et al., 1996) . To date, there is no evidence explicitly linking ventral tegmental area loss with cognitive dysfunction in PD (Jellinger, 1999) , although it is clear that mesocortical dopaminergic projections can influence cognitive function (Narayanan et al., 2012) .
Clinically, there is no correlation with classical nigrostriatal functions, such as bradykinesia or tremor (Cooper et al., 1991; Kieburtz et al., 1994) . Attempts to link cognitive dysfunction with motor features noted an association with akinetic forms of PD (Aarsland et al., 2003; Uc et al., 2009 ) and with axial/visuomotor dysfunction (Domell ö f et al., 2011), insinuating that other dopaminergic systems, such as mesocortical projections originating from the ventral tegmental area, may be involved. Future in-vivo molecular imaging studies of patients with early PD and cognitive dysfunction may address this question.
Dopamine signaling in the prefrontal cortex powerfully influences executive function (Arnsten and Li, 2005; Cools and D ' Esposito, 2011) . For instance, seminal work by Goldman-Rakic and colleagues demonstrated that blocking D1 receptors in the prefrontal cortex degraded single neuron activity encoding working memory (Williams and Goldman-Rakic, 1995; Goldman-Rakic et al., 2004; Wang et al., 2004) . In rodents, selectively blocking prefrontal D1 receptors impairs cognitive functions, such as interval timing (Narayanan et al., 2012) and memory (Seamans Floresco and Phillips, 2001) . Furthermore, dopamine release measured by microdialysis is correlated with working memory performance (Phillips et al., 2004) .
In humans, dopamine can be imaged using molecular imaging techniques, such as PET or single photon emission computed tomography (SPECT). However, these studies are complicated, because prefrontal dopamine signals are difficult to isolate (Vrieze et al., 2013) . Metabolic imaging (Huang et al., 2007) and presynaptic dopamine imaging (Ekman et al., 2012) have suggested an association with decreased anterior cingulate and caudate activation in patients with cognitive impairment in PD. In prefrontal regions, D1-type dopamine receptors are more prominent than D2-type receptors (Gaspar et al., 1995; Seong and Carter, 2012) . Despite these challenges, PET imaging shows that D1 signaling is modulated in frontal regions during working memory tasks (Okubo et al., 1997; Abi-Dargham et al., 2002) . PET scanning revealed a marked decrease in lateral and medial prefrontal dopamine and in D2 receptors in PD, albeit later in the disease (Rakshi et al., 1999; Kaasinen et al., 2000) . Curiously, in early PD, dopamine uptake has been reported to be increased in prefrontal regions (Rakshi et al., 1999; Cools et al., 2001; Kaasinen et al., 2001) , presumably related to frontal compensation. Increased dopamine could also produce cognitive dysfunction observed at first diagnosis (Aarsland et al., 2009 ), as cognitive processes require optimal dopamine (Cools and D ' Esposito, 2011) .
One other possibility is that dysfunctional striatal networks in PD involve both motor and cognitive pathways (Graybiel et al., 1994) . For instance, a decreased metabolic signal in frontal circuits is correlated with an altered signal in the pallidum (Dirnberger et al., 2005) , and that connectivity analysis revealed that pallido-frontal analysis could be modulated by levodopa (Jahanshahi et al., 2010) . Another study described altered dopamine release in the caudate and not the medial frontal cortex (Sawamoto et al., 2008) ; this altered dopamine release could explain dysfunctional prefrontal networks (Polito et al., 2012) .
Finally, genetic polymorphisms in frontostriatal circuits may interact with cognitive dysfunction. For instance, a polymorphism in catechol-o-methyl transferase was associated with poor planning in PD patients, as measured by the Tower of London task (Foltynie et al., 2004b) . Mutations in this gene also influence attention (Williams-Gray et al., 2008) and fronto-striatal circuitry (Wu et al., 2012) .
Cholinergic dysfunction
A final mechanistic contributor to cognitive symptoms of PD is the degeneration of non-dopaminergic ascending projection nuclei. Further analysis of the DATATOP study (Anon, 1989) found that cognitive symptoms of PD were correlated with subcortical features, such as bulbar and gastrointestinal symptoms, suggesting that autonomic, nondopaminergic projections may be involved (Uc et al., 2009) .
Indeed, PD involves degeneration of multiple ascending projection systems ( Figure 2 ) , including norepinephrine, serotonin, and dopamine (Scatton et al., 1983; Jellinger, 2011) , and prominently, acetylcholine. Cholinergic neurons in the basal forebrain are decimated in PD (Arendt et al., 1983) and develop Lewy-bodies (Candy, 1983) . Early pathological work linked cognitive symptoms in PD with decreased choline acetyltransferase (Fonnum, 1966) , an enzyme necessary for presynaptic synthesis of acetylcholine, and neuronal counts in the basal nucleus of Meynert (Perry et al., 1985) .
More recent molecular imaging techniques have identified cholinergic deficits in Parkinson ' s patients. For instance, PET and SPECT of nicotinic receptors have revealed widespread loss in Parkinson ' s patients with cognitive impairments (Fujita et al., 2006; Meyer et al., 2009) . In fact, cortical cholinergic function is more compromised in PD with dementia, compared to PD without dementia, which in turn shows worse cortical cholinergic function compared to Alzheimer ' s disease (Bohnen et al., 2003) . PET studies have also found decreased cortical and subcortical acetylcholinesterase in PD (Gilman et al., 2010) .
Acetylcholinesterase activity correlates with impaired executive function, but not motor symptoms (Bohnen et al., 2006) . Furthermore, acetylcholine has a potent modulatory role in thought disorders (Bosboom et al., 2003) . The strongest clinical link between cholinergic projections and PD comes from the EXPRESS study, which described several beneficial effects of treatment with rivastigmine, a cholinesterase inhibitor, which presumably increases the amount of acetylcholine present at the synaptic cleft. In this randomized, placebo-controlled study of 410 PD patients, a moderate improvement in a cognitive battery for PD patients with mild-moderate dementia was reported (Emre et al., 2004; Poewe et al., 2006) . Similar efforts with donepezil have been promising (Aarsland et al., 2002; Rowan et al., 2007) , but have been limited by side effects (Fabbrini et al., 2002; M ü ller et al., 2006) . This literature suggests that cholinergic signaling can be effectively modulated by oral drugs to improve executive function, psychosis, and dementia in Parkinson ' s patients, and future drugs might modulate this system, while minimizing dose-limiting side effects.
An interesting interface exists between cholinergic projection systems and dopamine systems involved in cognition. Parkinson ' s patients given small doses of anticholinergics, such as scopolamine, had impaired working memory (Dubois et al., 1987) . A follow-up study reported specific executive deficits with both trihexyphenidyl and scopolamine (B é dard et al., 1999) . We propose a model of cognitive dysfunction in PD associated with degeneration of forebrain-cortical cholinergic (Bohnen et al., 2003) and mesocortical/mesolimbic dopaminergic projections (Figures 1 and 2) (Bosboom et al., 2003) . The observed association between future cognitive impairment and cholinergically-modulated bulbar, gastrointestinal, and urologic symptoms in a large clinical trial cohort (Uc et al., 2009 ) lends indirect support to the cholinergic mechanisms on cognitive impairment in PD.
This model considers the possibility of interactions between cholinergic projections and mesocortical dopamine projections to the prefrontal cortex. Dysfunction in these projections could lead to executive dysfunction, as suggested by the modulation of the mesocortical circuits and prefrontal dopamine release by cholinergic signaling (Westerink et al., 1998) . Future studies that record from prefrontal neuronal networks, either intraoperatively (Sheth et al., 2012) , during epilepsy surgery (Garell et al., 2012) , or in animals (Narayanan and Laubach, 2006, 2009) can explicitly explore this idea.
Our model ( Figure 1 ) makes testable predictions that cholinergic and dopaminergic signaling interact on pyramidal neurons in the prefrontal cortex. Modulation of these receptors should profoundly influence neuronal networks correlated with executive function (Williams and Goldman-Rakic, 1995; Asaad et al., 1998) . While there is ample evidence that optimizing cholinergic signaling improves cognition in PD (Reading et al., 2001; Emre et al., 2004; Poewe et al., 2006; Schmitt et al., 2010) , we hypothesize that this benefit should interact with dopaminergic therapy. Future studies will investigate how rivastigmine and other cholinergic manipulations interact with levodopa therapy in PD patients.
Finally, prefrontal D1 signaling has been particularly implicated in executive processing impaired in PD Castner and Williams, 2007; Narayanan et al., 2012; Nikiforuk, 2012) . We suggest that D1 dopamine agonists may further potentiate cognitive effects of cholinergic agents. This idea can be studied at a mechanistic level with animal models, in order to generate new treatments for PD-related cognitive dysfunction.
Summary
In the present review, we have discussed cognitive dysfunction of PD involving executive dysfunction and disordered thought. There are no effective treatments for these symptoms, which may predict later amnestic disturbance, and lead to considerable morbidity and mortality. We evaluate a mechanistic possibility for executive dysfunction in PD, revolving around prefrontal dopamine systems, which could interact with cholinergic circuitry to produce executive dysfunction ( Figure 1 ). We are hopeful that further evaluation of the pathophysiology of cognitive dysfunction in PD will explore these ideas, as they may lead to new treatments that take advantage of either, or both of these powerful neuromodulatory systems.
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